Neil Garry Arthur Buys Shares of Celldex Therapeutics

Neil Garry Arthur recently acquired 26,000 shares of Celldex Therapeutics, Inc. (NasdaqCM:CLDX) on June 25, 2026. This insider purchase comes as shares of the biotechnology company traded at $35.26 on Tuesday.

Insider Buying and Selling at Celldex Therapeutics, Inc.

In addition to Neil Garry Arthur's acquisition, several other insiders also bought shares on June 25, 2026. Ronald Pepin, the Senior Vice President & Chief Business Officer, purchased 20,000 shares. Denice Torres, Martin Samuel Bates, the Senior Vice President and CFO, Margo Heath-Chiozzi, the SVP of Regulatory Affairs, and Sarah Cavanaugh, the SVP of Corporate Affairs & Administration, each bought shares as well, with Bates buying 93,000 shares and Heath-Chiozzi and Cavanaugh each acquiring 95,000 shares.

Celldex Therapeutics, Inc. Stock Down 4.3%

Shares of Celldex Therapeutics traded near $35.26 on Tuesday. The company, with a market cap of approximately $2.77 billion, operates in the biotechnology sector. Its forward P/E ratio isn't meaningful as the company is not currently profitable. Celldex's stock has fluctuated between a 52-week low of $19.52 and a high of $35.79. The stock's 50-day moving average is $32.10, and its 200-day moving average is $28.27. The company has a solid financial footing with a current ratio of 8.92 and a quick ratio of 8.78, alongside a debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

Analysts remain optimistic about Celldex Therapeutics. On June 15, 2026, HC Wainwright & Co. reiterated their buy rating with a price target of $42. UBS maintained its buy rating with a target of $45 on June 10, 2026. Wells Fargo also maintained a buy rating, setting a target of $54 on May 13, 2026. The consensus among analysts is a strong buy, with a target mean price of $57.53 based on 15 analyst opinions.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company is known for its clinical programs like Barzolvolimab, a monoclonal antibody targeting the KIT receptor to treat chronic urticarias and other conditions, and CDX-622, a bispecific candidate designed to address inflammatory diseases. Celldex employs approximately 198 people and is led by CEO Mr. Anthony S. Marucci.

Bottom Line

Neil Garry Arthur's recent purchase is part of a broader insider buying activity at Celldex Therapeutics, suggesting confidence in the company's prospects. While the company's financials reflect its developmental stage, analysts' strong buy ratings and price targets indicate positive expectations. As always, remember that insider buying can be a positive signal, but it's important to consider the broader context and market conditions.